The American Society for Pharmacology and Experimental Therapeutics and Elsevier Partner to Publish the Society’s Journals

Elsevier, a global leader in scientific information and data analytics, and The American Society for Pharmacology and Experimental Therapeutics(打開新的分頁／視窗) (ASPET), are partnering to publish the Society’s four journals. ASPET’s journals, The Journal of Pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, Molecular Pharmacology and Pharmacological Reviews, will be published in collaboration with Elsevier beginning early next year. The partners are committed to a relationship that will allow long-term growth and security for the Society and its journals.

The ASPET-Elsevier partnership will expand the usage of innovative technologies leading to opportunities to increase submissions. ASPET staff and editors will have access to new analytical, bibliometric and plagiarism detection software tools. Authors will be able to publish free with no submission fees or page charges with an option for open access.

ASPET editors, journal boards and staff will continue to manage the journals with full editorial control. ASPET and Elsevier will work together to ensure a smooth transition.

“The decision to partner with Elsevier was the result of a multi-year process using expert publishing consultants that guided ASPET through a diligent analysis of how best to move ASPET’s journals forward. After years of research and discussion, it was determined that partnering with Elsevier was the best pathway forward for ensuring the continued success of ASPET journals. This partnership fully supports ASPET’s strategic focus of being the authoritative scientific resource for pharmacology,” explained ASPET President Namandjé Bumpus.

ASPET began publishing its first journal in 1908, and the Society has been committed to the success of its journals since then. The ASPET founders laid the groundwork for sharing science with the larger pharmacology community to help advance the science of drugs and therapeutics to accelerate the discovery of cures for disease.

“At a time when the publishing industry has never been more competitive and uncertain, ASPET is very excited to be partnering with an organization with the experience, expertise and capabilities that Elsevier brings to the table,” stated ASPET Executive Officer Dave Jackson.

“We at Elsevier are delighted and honored that ASPET has chosen us as their publishing partner after over a hundred years of publishing leading work in pharmacological research. Our shared commitment to high quality, rigor and research integrity will lead to a productive partnership that will continue ASPET’s great traditions,” remarked Louise Curtis, Elsevier Senior Vice President, Life Sciences, Social Sciences, Economics.

“This partnership will help ASPET journal authors maximize their impact globally and support the editorial teams and staff at ASPET meet the challenges of a changing publishing landscape,” Curtis added.

ASPET’s move from a self-publishing model to a publisher-partnership with Elsevier will better serve its authors, reviewers and the Society as a whole. ASPET’s already existing journals will remain hybrid, as access will continue to be subscription-based with the option for authors to publish as Open Access.

“We believe this partnership has the potential to improve an already excellent author experience, provide more support and new tools to our reviewers and editors, and further expand the reach of our influential journals,” Jackson pointed out.

Notes to Editors

About ASPET

The American Society for Pharmacology and Experimental Therapeutics (ASPET), founded in 1908, is an international 4,000-member non-profit pharmacology society that advances the science of drugs and therapeutics to accelerate the discovery of cures for disease. ASPET members conduct basic and clinical pharmacological research in academia, industry and the government. ASPET publishes four journals with the most recent discoveries in pharmacology and related fields. ASPET supports the dissemination and use of pharmacological research to promote the best available science in developing regulations and legislation. ASPET is headquartered in Rockville, Md. Visit aspet.org to learn more.

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation(打開新的分頁／視窗), we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX(打開新的分頁／視窗), a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.